We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A health information industry group has asked HHS Secretary Tommy Thompson to use any undesignated and/or unspent discretionary funds in the department’s budget to support HHS’ new Office of the National Coordinator for Health Information Technology (ONCHIT).
HHS Secretary Tommy Thompson announced his letter of resignation Dec. 5. In a letter to department staff, Thompson, a former four-term governor of Wisconsin, praised the HHS’ 67,000 employees and listed HHS’ major accomplishments during his tenure.
GlaxoSmithKline (GSK) will sell 1.2 million doses of its influenza vaccine, Fluarix, to HHS after the FDA authorized the importation of the product into the U.S. under an investigational new drug application (IND).
The federal government will sponsor a clinical trial at four test sites to measure the safety and efficacy of Fluarix, an influenza vaccine manufactured by GlaxoSmithKline (GSK) that hasn’t been approved for use in the U.S.
The FDA’s much-touted Critical Path Initiative to expedite the drug development process has been delayed as other issues, including safety concerns about marketed drugs, have drawn the agency’s attention.
HHS will immediately purchase 1.2 million doses of GlaxoSmithKline’s (GSK’s) influenza vaccine, Fluarix, after the FDA authorized the importation of the product into the U.S. under an investigational new drug application, Secretary Tommy Thompson announced yesterday.
HHS Secretary Tommy Thompson announced he would be resigning as secretary of HHS. He becomes the eighth member of the Bush Cabinet to decline serving a second term.
The FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC) has issued an untitled letter to Boehringer Ingelheim, citing the company for a sales aid promoting its antihypertensive drug, Micardis.
A follow-up study performed by HHS' Office of Inspector General (OIG) confirmed that some pharmaceutical firms in 2002 overcharged public-health facilities participating in a federal drug-discount program by tens of millions of dollars.
Pharmaceutical firms shouldn't be allowed to determine what drugs the Medicare program will pay for under the new Rx benefit, according to seniors surveyed by the trade group representing pharmaceutical benefit managers (PBMs).